Clinical Trial: NCT04547504
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | University Hospital, Brest |
| Information Provided By: | University Hospital, Brest |
| Last Update Posted: | 2025-09-17 |
Study Overview
Brief Summary
PERSEE is a French national phase 3 academic study comparing the chemotherapy-pembrolizumab combination to pembrolizumab alone as a first-line treatment for advanced NSCLC molecularly defined by a PDL1 expression ≥ 50% of tumour cells and no EGFR mutations or ALK rearrangement.
The main hypothesis is the superiority of the chemo-immunotherapy combination over mono-immunotherapy in terms of progression-free survival evaluated by an independent review committee.
One of the anticipated benefits of using the chemotherapy-pembrolizumab combination starting from the first line setting for NSCLC patients with PD L1 ≥ 50% is a reduced risk of early progression, which is known to occur with pembrolizumab monotherapy, and therefore, a better PFS.
Official Title
Conditions
Intervention / Treatment
- Drug: Pembrolizumab
- Drug: Pembrolizumab and Chemotherapy drugs
Other Study ID Numbers
- 29BRC20.0159_GFPC01-2020
- GFPC 01-2020
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | University Hospital, Brest |
| Information Provided By: | University Hospital, Brest |
| Last Update Posted: | 2025-09-17 |
Study Overview
Brief Summary
PERSEE is a French national phase 3 academic study comparing the chemotherapy-pembrolizumab combination to pembrolizumab alone as a first-line treatment for advanced NSCLC molecularly defined by a PDL1 expression ≥ 50% of tumour cells and no EGFR mutations or ALK rearrangement.
The main hypothesis is the superiority of the chemo-immunotherapy combination over mono-immunotherapy in terms of progression-free survival evaluated by an independent review committee.
One of the anticipated benefits of using the chemotherapy-pembrolizumab combination starting from the first line setting for NSCLC patients with PD L1 ≥ 50% is a reduced risk of early progression, which is known to occur with pembrolizumab monotherapy, and therefore, a better PFS.
Official Title
Conditions
Intervention / Treatment
- Drug: Pembrolizumab
- Drug: Pembrolizumab and Chemotherapy drugs
Other Study ID Numbers
- 29BRC20.0159_GFPC01-2020
- GFPC 01-2020